Predict your next investment

Private Equity
deeptrackcapital.com

See what CB Insights has to offer

Investments

9

Portfolio Exits

2

About Deep Track Capital

Deep Track Capital is a Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry.

Deep Track Capital Headquarter Location

200 Greenwich Ave 3rd Floor

Greenwich, Connecticut, 06830,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Deep Track Capital News

Silence Therapeutics Welcomes Deep Track Capital as New Shareholder

Dec 1, 2021

1 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Deep Track Capital, a U.S. investment firm focused exclusively on the life sciences industry, purchased approximately $22 million of American Depository Shares (ADSs) in Silence from existing shareholders. Gerard Smith, M.D., Principal at Deep Track Capital, said: “Silence has a promising wholly-owned clinical stage pipeline in addition to its proprietary mRNAi GOLD™ platform that we believe could drive long term growth and value creation for patients and shareholders. We look forward to supporting the Silence team in the journey ahead.” Mark Rothera, President and Chief Executive Officer at Silence, said: “We are excited to have Deep Track Capital’s support as we initiate our next phase of growth based on maximizing the opportunity of our proprietary mRNAi GOLD™ platform. Next year is set to be another big year for the Company, starting with topline data from our wholly owned SLN360 program for high lipoprotein(a) anticipated in the first quarter of 2022.” Craig Tooman, Chief Financial Officer at Silence, said: “Yesterday marked our first day of trading exclusively on Nasdaq, a move we made to support increasing interest from new investors. We are very pleased to have Deep Track Capital join our expanding U.S. institutional shareholder base and expect this trend to continue.” Enquiries: About Silence Therapeutics Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron-loading anemia conditions. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit  https://www.silence-therapeutics.com/ . Forward-Looking Statements Certain statements made in this announcement are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company's clinical and commercial prospects and the anticipated timing of data reports from the Company's clinical trials. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including those risks identified in the Company's most recent Admission Document and its amended Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on April 29, 2021. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Deep Track Capital Investments

9 Investments

Deep Track Capital has made 9 investments. Their latest investment was in Silence Therapeutics as part of their PIPE on December 12, 2021.

CBI Logo

Deep Track Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/1/2021

PIPE

Silence Therapeutics

$22M

Yes

1

11/9/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

9/9/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

8/24/2021

Series C - II

Subscribe to see more

$99M

Subscribe to see more

10

8/18/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/1/2021

11/9/2021

9/9/2021

8/24/2021

8/18/2021

Round

PIPE

Series B

Series B

Series C - II

Series B

Company

Silence Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$22M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Deep Track Capital Portfolio Exits

2 Portfolio Exits

Deep Track Capital has 2 portfolio exits. Their latest portfolio exit was Vigil Neuroscience on January 07, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/7/2022

IPO

2

9/15/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/7/2022

9/15/2021

Exit

IPO

IPO

Companies

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Sources

2

10

Deep Track Capital Team

1 Team Member

Deep Track Capital has 1 team member, including current Founder, Chief Investment Officer, David E. Kroin.

Name

Work History

Title

Status

David E. Kroin

Great Point Partners, and Merrill

Founder, Chief Investment Officer

Current

Name

David E. Kroin

Work History

Great Point Partners, and Merrill

Title

Founder, Chief Investment Officer

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.